MedTrace Logo

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

NCT02705508 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-06-18

No results posted yet for this study

Summary

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of pegylated aspargase(PEG-ASP)combined with etoposide and gemcitabine (PEG) treatment in this population.

Conditions

  • Treatment Refusal

Interventions

DRUG

Gemcitabine

1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.

DRUG

etoposide

100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.

DRUG

Pegaspargase

2500U/m2 im on day 1 of each 21 day cycle.

RADIATION

involved-field radiotherapy

Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.

Sponsors & Collaborators

  • China Food and Drug Administration

    collaborator OTHER_GOV

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • hua wang, MD. · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02705508 on ClinicalTrials.gov